Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Multiple intraepithelial neoplasias of the lower female genital tract: the reliability of HPV mRNA test.

Frega A, Sesti F, Sopracordevole F, Biamonti A, Votano S, Catalano A, Milazzo GN, Gentile M, Ricciardi E, French D, Moscarini M.

J Low Genit Tract Dis. 2014 Apr;18(2):174-81. doi: 10.1097/LGT.0b013e31829706bc.

PMID:
23994947
2.

Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study.

Broccolo F, Fusetti L, Rosini S, Caraceni D, Zappacosta R, Ciccocioppo L, Matteoli B, Halfon P, Malnati MS, Ceccherini-Nelli L.

J Med Virol. 2013 Mar;85(3):472-82. doi: 10.1002/jmv.23487. Epub 2012 Dec 26.

PMID:
23280876
3.

Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA- and E6/E7 mRNA-based assays of HPV DNA positive women with abnormal Pap smears.

Salimović-Bešić I, Tomić-Čiča A, Smailji A, Hukić M.

J Virol Methods. 2013 Dec;194(1-2):222-8. doi: 10.1016/j.jviromet.2013.08.036. Epub 2013 Sep 13.

PMID:
24036071
4.

Multifocal vulvar intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papillomavirus.

van Beurden M, ten Kate FJ, Smits HL, Berkhout RJ, de Craen AJ, van der Vange N, Lammes FB, ter Schegget J.

Cancer. 1995 Jun 15;75(12):2879-84.

5.

Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.

Liu TY, Xie R, Luo L, Reilly KH, He C, Lin YZ, Chen G, Zheng XW, Zhang LL, Wang HB.

J Virol Methods. 2014 Feb;196:120-5. doi: 10.1016/j.jviromet.2013.10.032. Epub 2013 Nov 9.

PMID:
24216236
6.

Human papillomavirus DNA and mRNA positivity of the anal canal in women with lower genital tract HPV lesions: predictors and clinical implications.

Valari O, Koliopoulos G, Karakitsos P, Valasoulis G, Founta C, Godevenos D, Dova L, Paschopoulos M, Loufopoulos A, Paraskevaidis E.

Gynecol Oncol. 2011 Sep;122(3):505-8. doi: 10.1016/j.ygyno.2011.05.033. Epub 2011 Jun 12.

PMID:
21665253
7.

Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.

Tropé A, Sjøborg KD, Nygård M, Røysland K, Campbell S, Alfsen GC, Jonassen CM.

J Clin Microbiol. 2012 Jun;50(6):1927-35. doi: 10.1128/JCM.00265-12. Epub 2012 Apr 18.

8.

Prevalence of human papillomavirus genomes in tissues from the lower genital tract as detected by molecular in situ hybridization.

Schneider A, Meinhardt G, Kirchmayr R, Schneider V.

Int J Gynecol Pathol. 1991;10(1):1-14.

PMID:
1848832
9.

Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia.

Tropé A, Sjøborg K, Eskild A, Cuschieri K, Eriksen T, Thoresen S, Steinbakk M, Laurak V, Jonassen CM, Westerhagen U, Jacobsen MB, Lie AK.

J Clin Microbiol. 2009 Aug;47(8):2458-64. doi: 10.1128/JCM.01863-08. Epub 2009 Jun 17.

10.

Hybrid Capture II testing for high-risk human papillomavirus DNA in the follow-up of women treated for high-grade cervical intraepithelial neoplasia.

Tan JH, Garland SM, Tabrizi SN, Moore EE, Danielewski JA, Quinn MA.

J Low Genit Tract Dis. 2013 Jul;17(3):308-14. doi: 10.1097/LGT.0b013e31826cd7c1.

PMID:
23552206
11.

Analyses of human papillomavirus genotypes and viral loads in anogenital warts.

Ball SL, Winder DM, Vaughan K, Hanna N, Levy J, Sterling JC, Stanley MA, Goon PK.

J Med Virol. 2011 Aug;83(8):1345-50. doi: 10.1002/jmv.22111.

PMID:
21678438
12.

High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.

Rijkaart DC, Heideman DA, Coupe VM, Brink AA, Verheijen RH, Skomedal H, Karlsen F, Morland E, Snijders PJ, Meijer CJ.

J Clin Microbiol. 2012 Jul;50(7):2390-6. doi: 10.1128/JCM.06587-11. Epub 2012 May 2.

13.

RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus.

Cattani P, Siddu A, D'Onghia S, Marchetti S, Santangelo R, Vellone VG, Zannoni GF, Fadda G.

J Clin Microbiol. 2009 Jul;47(7):2136-41. doi: 10.1128/JCM.01733-08. Epub 2009 Apr 29.

14.

Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia.

Andersson E, Kärrberg C, Rådberg T, Blomqvist L, Zetterqvist BM, Ryd W, Lindh M, Horal P.

J Clin Microbiol. 2011 Nov;49(11):3794-9. doi: 10.1128/JCM.00549-11. Epub 2011 Sep 21.

15.
16.

Human papillomavirus types 6 and 16 in multifocal intraepithelial neoplasias of the female lower genital tract.

McCance DJ, Clarkson PK, Dyson JL, Walker PG, Singer A.

Br J Obstet Gynaecol. 1985 Nov;92(11):1093-100.

PMID:
2998437
17.

Human papillomaviruses and multifocal genital neoplasia.

Hording U, Daugaard S, Junge J, Lundvall F.

Int J Gynecol Pathol. 1996 Jul;15(3):230-4.

PMID:
8811384
18.

Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA.

Perez Castro S, Iñarrea Fernández A, Lamas González MJ, Sarán Diez MT, Cid Lama A, Alvarez Martín MJ, Pato Mosquera M, López-Miragaya I, Estévez N, Torres Piñón J, Oña Navarro M.

J Med Virol. 2013 Jun;85(6):1063-8. doi: 10.1002/jmv.23544.

PMID:
23588733
19.

Detection of human papillomavirus (HPV) in genital warts and carcinomas by DNA in situ hybridization in Chinese patients.

Chang F, Syrjänen S, Shen Q, Ji H, Syrjänen K.

Cytopathology. 1990;1(2):97-103.

PMID:
1966324
20.

Supplemental Content

Support Center